The Medicines and Healthcare products Regulatory Agency (MHRA) has restated its test for what counts as a medicine, after a University of Lincoln academic called for the 'research use only' route to be closed.
Dr Luke Turnock, a senior lecturer in criminology at the University of Lincoln who researches the trade and misuse of drugs, told BBC News that the online availability of peptides carrying a 'research use only' or 'not for human consumption' disclaimer was one of his main concerns. He described the disclaimer as a way of evading medicines rules: a seller is not permitted to sell a product as a medicine, but stating that it is a research chemical makes enforcement harder.
'The MHRA determines whether a product is a medicine on a case-by-case basis,' the regulator told the BBC. 'If a product is classified as a medicine and is not appropriately authorised, we take regulatory compliance action.' The MHRA added that it disregards claims that products are for research purposes if it is clear that such claims are being used as an attempt to avoid medicines regulations.
Why the label does not decide the question
Under the Medicines Act 1968 and the Human Medicines Regulations 2012, a product can be a medicine either by presentation or by function. Presentation turns on how the product is described and promoted; function turns on what it does in or on the body. A disclaimer printed on a vial does not override either limb. If a product is presented for a medicinal purpose, or acts pharmacologically to modify bodily function, the MHRA can treat it as a medicine regardless of the words on the packaging — that is the point the regulator is restating.
The same rules mean that peptides genuinely supplied for laboratory research, with no medicinal claim and no human-use framing, are not medicines. This site's standing position is that research peptides are research compounds only. Nothing here is consumption advice; the regulatory story is about the boundary between the two uses, not a route across it.
What Turnock argued
Turnock said his concern was not acute harm alone but the delayed kind. Products that cause longer-term harms — he named increased cancer risk and internal organ damage as possibilities — may not produce an immediate side effect, so a user might not connect a later problem to a product used over a prolonged period. He called tightening the 'research use only' route 'the first step'.
What the MHRA has said before
The MHRA line reported by the BBC is consistent with the position it has taken in recent UK enforcement. Many peptides sold for use in recreational sport, and not accompanied by medicinal claims, are not treated as medicines. Where a product is classified as a medicine and is unauthorised, the agency's stated response is regulatory compliance action rather than a general ban on the category. In practice the classification is fact-specific, which is why the same molecule can sit on either side of the line depending on how it is sold and described.
What this means for the sector
The story is an enforcement and policy signal, not evidence about any individual compound. The UK framework it turns on is unchanged: the Medicines Act 1968, the Human Medicines Regulations 2012, and the MHRA's case-by-case assessment. What is moving is pressure to apply those rules to products marketed with a research disclaimer, and a call — from an academic, not yet from government — to close the gap the disclaimer is said to exploit.
For readers of this reference, the practical consequence is a clearer statement of the boundary rather than a change to it. A 'research use only' label is not a regulatory shield, and it is not a licence. It is a factual description of intended use — and the MHRA has said plainly that it will look at the reality behind it.
This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.